Pancreatic Cancer Research

ResearcherOslo University HospitalActive in the last 2 years

Manoj Amrutkar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1868-0249; OpenAlex author ID A5053683423. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 3 papers · 2024: 1 paper · 2025: 4 papers · 2026: 2 papers

Papers 17

  1. Reduced lipid metabolite abundance in human pancreatic cancer and matched serum samples following neoadjuvant FOLFIRINOX treatment. Co-author DOI 10.1007/s11306-025-02388-z↗
  2. Proteomic characterization of primary pancreatic fibroblasts derived from neoadjuvant chemotherapy treated versus treatment-naïve PDAC. Co-author DOI 10.1016/j.jprot.2026.105660↗
  3. Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreat… Co-author DOI 10.1002/1878-0261.13759↗
  4. Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41597-025-04522-x↗
  5. Knowledge Discovery in Databases of Proteomics by Systems Modeling in Translational Research on Pancreatic Cancer. Co-author DOI 10.3390/proteomes13020020↗
  6. Proteomic Characterization of Primary Human Pancreatic Cancer Cell Lines Following Long-Term Exposure to Gemcitabine. Co-author DOI 10.3390/proteomes13040048↗
  7. Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems. Co-author DOI 10.1016/j.semcancer.2024.09.002↗
  8. Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.13344↗
  9. Pancreatic stellate cell-induced gemcitabine resistance in pancreatic cancer is associated with LDHA- and MCT4-mediated enhanced glycolysis. Co-author DOI 10.1186/s12935-023-02852-7↗
  10. Fatty acids abrogate the growth-suppressive effects induced by inhibition of cholesterol flux in pancreatic cancer cells. First author DOI 10.1186/s12935-023-03138-8↗
  11. Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer. Co-author DOI 10.3390/cancers13040601↗
  12. Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence. Co-author DOI 10.3390/cancers13040895↗
  13. Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing. Co-author DOI 10.3390/cancers12123628↗
  14. Establishment and Characterization of Paired Primary Cultures of Human Pancreatic Cancer Cells and Stellate Cells Derived from the Same Tumor. Co-author DOI 10.3390/cells9010227↗
  15. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. Co-author DOI 10.1186/s12885-019-5803-1↗
  16. Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer Cells. First author DOI 10.3390/cells8010023↗
  17. Pancreatic Cancer Chemoresistance to Gemcitabine. Co-author DOI 10.3390/cancers9110157↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ivar P. Gladhaug · 14 shared papers, 2017–2026 · strength 3.00
  2. Caroline Sophie Verbeke · 14 shared papers, 2019–2026 · strength 2.98
  3. Knut Jørgen Labori · 4 shared papers, 2023–2026 · strength 1.19
  4. Mathilde Resell · 2 shared papers, 2025 · strength 0.41
  5. Chun‐Mei Zhao · 2 shared papers, 2025 · strength 0.41
  6. Surinder K. Batra · 2 shared papers, 2025 · strength 0.41
  7. Timothy Cragin Wang · 2 shared papers, 2025 · strength 0.41
  8. Anil K. Rustgi · 2 shared papers, 2025 · strength 0.41
  9. Petra Sántha · 3 shared papers, 2019–2021 · strength 0.37
  10. Daniela M. Lenggenhager · 2 shared papers, 2019–2021 · strength 0.25
  11. Yuchuan Li · 1 shared paper, 2023 · strength 0.22
  12. Benoît Immordino · 1 shared paper, 2024 · strength 0.19
  13. Macarena Perán · 1 shared paper, 2024 · strength 0.19
  14. Naomi Walsh · 1 shared paper, 2024 · strength 0.19
  15. Cristina P. R. Xavier · 1 shared paper, 2024 · strength 0.19
  16. Rita Rebelo · 1 shared paper, 2024 · strength 0.19
  17. Alessandro Gregori · 1 shared paper, 2024 · strength 0.19
  18. Belén Toledo · 1 shared paper, 2024 · strength 0.19
  19. Giulia Lencioni · 1 shared paper, 2024 · strength 0.19
  20. Justo Pastor Castano · 1 shared paper, 2024 · strength 0.19
  21. Elisa Giovannetti · 1 shared paper, 2024 · strength 0.19
  22. Matthias J. Löhr · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.